Dr. Jim LeDuc Director Galveston National Laboratory University of Texas Medical Branch. 29 October 2015

Similar documents
Institutional Laboratory Biosafety Manual

University of Hawaii Biosafety Program Laboratory Inventory and Declaration Form

STOP! These are some Symbols below that are Violations! PLEASE CHECK ALL SIX (6) SIDES OF YOUR BOX BEFORE SHIPPING

Plant Pathogen Select Agents: Revised Rule Biocontainment Requirements

Infectious Material. hazmat.dot.gov/regs/rules.htm iata.org/dangerousgoods

SCHEDULE 5 PATHOGENS AND TOXINS VIRUSES

SELECT BIOLOGICAL AGENTS POLICY

Sample collection and shipping. disinfection

FEDERAL REGISTER Hazardous Materials: Infectious Substances; Harmonization With the United Nations Recommendations

FEDERAL REGISTER Hazardous Materials: Infectious Substances; Harmonization With the United Nations Recommendations

Mount Sinai Medical Center Environmental Health & Safety (EnvHS)

THE UNIVERSITY OF MISSISSIPPI LABORATORY SERVICES Phone (662) FAX (662)

Guidance on regulations for the Transport of Infectious Substances

Cal OSHA Title 8, Section 5199 Appendix D: Aerosol Transmissible Pathogens Laboratory

Bioterrorism and Biosecurity in the United States

TECHNICAL INSTRUCTIONS FOR THE SAFE TRANSPORT OF DANGEROUS GOODS BY AIR

Federal Select Agent Program Overview

Agents of Bioterrorism: Argument for and Against a List That Needs Cropping

Dangerous Goods Regulations

Pathogens and Toxins Guidance. ATCSA 2001 Schedule 5 Order 2007 Notes (SI 2007/929)

Yorkhill Laboratories Policy for the Packaging and Transport of Biological Samples (sent from laboratories) H&S/Doc/07. Yorkhill Hospitals

Classification of Infectious Substances. Substances

secondary packaging, but sufficient additional absorbent material shall be used to absorb all fluid in case of breakage.

Ethic Problems Related to the Microorganisms

CBEP Biosciences Fellowship Program Program Summary

Our Directory of Services (DOS): /view/general/1496/

CTR Biosciences Fellowship Program Program Summary. Laboratory operations, research, and diagnostics.

Regulations. Bloodborne Pathogens. Applicability. Biological Agents and Blood borne Pathogens

INTERfering and Co-Evolving Prevention and Therapy (INTERCEPT) Proposers Day

Index. Infect Dis Clin N Am 20 (2006) Note: Page numbers of article titles are in boldface type.

Occupational Health Program Guidance Document for Working with Tier 1 Select Agents and Toxins

Yale Environmental Health & Safety Update Form for Request to Use Infectious Agents Status of Protocol

Emerging Select Agent Issues and Regulations

WHAT WILL WE LEARN FROM ESEI RESEARCH?

Appendix B: Provincial Case Definitions for Reportable Diseases

Overview of Export Controlled pathogens and toxins.

Transport of Infectious Substances

Infectious Diseases Weekly Report. 14 March 2013 / Number 10

Infectious Diseases Weekly Report. 12 January 2018 / Number 1. The infectious diseases which all physicians must report

Infectious Diseases Weekly Report. 23 August 2018 / Number 33. The infectious diseases which all physicians must report

Infectious Diseases Weekly Report. 8 November 2018 / Number 44. The infectious diseases which all physicians must report

Infectious Diseases Weekly Report. 15 November 2018 / Number 45. The infectious diseases which all physicians must report

Infectious Diseases Weekly Report. 14 March 2019 / Number 10. The infectious diseases which all physicians must report

Infectious Diseases Weekly Report. 22 March 2019 / Number 11. The infectious diseases which all physicians must report

Infectious Diseases Weekly Report. 28 March 2019 / Number 12. The infectious diseases which all physicians must report

Infectious Diseases Weekly Report. 4 April 2019 / Number 13. The infectious diseases which all physicians must report

Infectious Diseases Weekly Report. 11 April 2019 / Number 14. The infectious diseases which all physicians must report

Fort Detrick Area B11 Removal Action Update

Prof. Dr. Reinhard Burger Robert Koch-Institut

Interstate Shipment of Etiologic Agents 42 CFR Part 72

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL INTERIM REPORT 02_2013

2 Bio/Agro Security Enterprise Historical Context and Scope

Notes from the Sentinel Liaison

An Overview of Bioterrorism. SAEMS January 30, Charles A. Schable, M.S. Institutional Biosafety Committee University of Arizona

Biological Warfare Agents

Viral Hemorrhagic Fevers CDC, AFIP

One World One Health TM

COMMUNICATING IN A CRISIS

Biological Warfare Agents

Bioterrorism: Public Health Challenges (Module 1: Bioterrorism Overview and History of Biological Warfare)

EPIDEMICS AND PANDEMICS: PREDICTION, PREVENTION, CONTROL?

A Survey of Asian Life Scientists: The State of Biosciences, Laboratory Biosecurity, and Biosafety in Asia

Infectious Disease Control Law of Japan and Biorisk management in NIID NIID 国立感染症研究所. July 10, 2008, Seoul, Korea

NIAID Biodefense Research Agenda

Before you begin, in order to conserve your efforts, notify/contact Don Michael Hooks, Office of Environmental Health & Safety (EHS),

GAO. Testimony Before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives

Viral Hemorrhagic Fevers

A BSL-1 lab houses activities that require only standard microbial practices. These include:

Implementation Manual for the National Epidemiological Surveillance of Infectious Diseases Program

National Institute of Allergy and Infectious Diseases Biodefense Research Agenda for NIAID Category B and C Priority Pathogens.

Revised forms for the submission of the Confidence-Building Measures

Animal Disease Surveillance in South Africa. Submitted by South Africa

Testing for SSBA (Security Sensitive Biological Agents) Dr Torsten Theis Senior Hospital Scientist RCPA BioSecurity QAP 16 August 2012

International Emerging Infections Program A Program to Build Capacity to Address Emerging Infections in Africa

health professionals will need to be familiar with the effects of these agents and the treatment of associated casualties. _ Jim Carson, 1997

Food Defense: The Necessity of Its Implementation in Indonesia

Note: Reports cover the period

ESTABLISHMENT OF A CRYO-ELECTRON MICROSCOPY LABORATORY UNDER BSL-3 CONDITIONS

Laboratory Biosecurity: A Survey of the U.S. Bioscience Community

BIOSAFETY NEWS 1 st Edition

Indonesia s challenges and needs in improving national capabilities for disease surveillance, detection and diagnosis and public health systems:

Successful Collaboration and Preparedness in Global Governance

Laboratory diagnosis Surveillance and outbreak detection Outbreak investigation

Import Health Standard. For. Bovine Embryos

Public Health Laboratories and IHR - Efficient response to highly dangerous and emerging pathogens at EU level

Current strategies, initiatives and challenges to mitigate biorisk: Indonesia s experience

Economic and Social Council

Association of Public Health Laboratories

INTRODUCTORY CHAPTERS SAMPLING METHODS

Viral Haemorrhagic Fevers

Science Applied to. Saving Lives. Uganda s Progress in. Implementing Lab. Biosafety / Biosecurity

Bioterrorism Capabilities in Rural Texas Hospitals and Laboratories by

BIOTERRORISM DISEASES / AGENTS: A Visual Guide for US Air Force Public Health Officers

Continuing Education Material: Biological and Chemical Terrorism. ABP, Inc

RESEARCH WITH HIGHLY PATHOGENIC AVIAN INFLUENZA H5N1

Introduction History Epidemiology Current outbreak Mode of transmission Replication Pathogenesis Diagnosis Prevention Animal models

Travel and transport risk assessment. Preparedness for potential outbreak of

Establishment of networks of human and animal virology laboratories and medical entomology

One Health: A Concept for the 21 st Century

Transcription:

National Academy of Sciences Committee on Federal Regulations and Reporting Requirements: A new framework for research universities in the 21 st Century Select Agents Dr. Jim LeDuc Director Galveston National Laboratory University of Texas Medical Branch 29 October 2015

Select Agents Currently Registered for Research HHS Select Agents and Toxins Coxiella burnetii Crimean-Congo hemorrhagic fever virus Eastern Equine Encephalitis virus Ebola virus Francisella tularensis Lassa fever virus Lujo virus Marburg virus Monkeypox virus Reconstructed 1918 Influenza virus Rickettsia prowazekii South American Haemorrhagic Fever viruses: Guanarito, Junin, Machupo, Sabia Tick-borne encephalitis complex (flavi) viruses: Far Eastern Tickborne encephalitis, Tick-borne encephalitis (Siberian Subtype) Kyasanur Forest disease Omsk Hemorrhagic Feverr Yersinia pestis Overlap Select Agents and Toxins Bacillus anthracis Bacillus anthracis Pasteur strain Brucella abortus Brucella melitensis Burkholderia mallei (formerly Pseudomonas mallei) Burkholderia pseudomallei (formerly Pseudomonas pseudomallei) Hendra virus Nipah virus Rift Valley fever virus Venezuelan Equine Encephalitis virus USDA Select Agents and Toxins Avian influenza virus (highly pathogenic Newcastle disease virus Vesicular stomatitis virus (exotic): Indiana subtypes VSV-IN2, VSV-IN3 Virulent Newcastle disease virus

National Bio and Agro-Defense Facility (DHS 2022) University of Florida

NBL-RBL Network

Programmatic Costs to the University Physical plant construction costs Recurrent operations costs to ensure proper safety and security Security costs guards, cameras, locks, 24/7 coverage, enhanced IT security structure Personnel screening costs background/medical Costs of providing investigator biosafety training Time required for biosafety training Tier 1 enhanced access control

Personnel Challenges Background Checks - UTMB background check - DSAT background check Medical clearance for BSL4 workers and Tier 1 workers Personal Reliability Program for all Tier 1 workers Lack of mechanism to allow an individual to contest a failed background check

Inspections Frequency of inspections; (we average about 3/year) Impact on staff time to host inspection team - preparation for the visit-review inventories (1 week) - during the visit, including entrance and exit interviews (1 to 2 weeks) - cost of PPE (typically supplied by us) - responding to findings agent inventories Questionable quality (experience) of inspectors Inspections by both CDC and USDA

Inventory Maintenance & Record-Keeping Replicating agents: thus entire premise of counting vials is flawed Repeated freeze-thaw cycles impacts specimen viability Cost of creating and maintaining inventories (individual log books or automated systems) Unintended consequences of counting vials: risk of vials sticking to gloves and loss. (We had the inspectors do this on last visit) Negative perception in community when record errors are found and made public Questionable value of follow-up investigations by campus police and FBI Recent expansion to include animal tissues, carcasses and other working stocks We should be held accountable for the safe and secure handling of select agents, but we should not be counting vials.

Reports and Formal Communications Delay in receiving inspection reports (months), but entity response to reports is required within 2 weeks Delays in CDC/USDA response to requests for approval for individuals to handle select agents (months) Impact on our ability to conduct funded research in a timely manner Adequate staffing levels at CDC & USDA?

Specimen Shipment Administrative burden associated with shipping and receiving, especially internationally Lack of approved carriers after the Dugway anthrax incident FEDEX will no longer ship select agents Only one experienced U.S. carrier, with limited distribution network and significantly increased costs

Export Control Regulations on Biological Items Commerce Control List of viruses and bacteria of public health and agricultural importance Controls export internationally The list is different from select agents list Agents determined by the Australia Group of 41 countries to maintain a list of biological agents that could be used in biological warfare Serious repercussions for failure to get approvals Dengue example

Unintended Consequences Limited work being done on critical pathogens of Public Health and national security importance Investigators use surrogates rather than actual pathogens Many highly qualified researchers leave the field or refuse to work on select agents Collaborations more challenging, especially internationally Exchange of specimens very difficult, leading to isolation of US investigators from international outbreaks/investigations Negative impact on national security and public health preparedness: we are isolating ourselves from the world Risk of existing facilities closing select agent programs due to operational costs

Health Security Volume 13, Number 4, 2015 the Division of Select Agents and Toxins employs more than 150 people. In FY2015, the select agent program received an estimated $16.6 million, not including working capital fund expenses and other associated costs. For 2016, the program will ask for an additional $10 million to improve and increase regulation and oversight of select agents and toxins, and plans to increase the number of annual inspections and surprise visits for what are termed high risk facilities by 25%. Will expanding this program make us safer or more secure? Or will it further slow progress in domestic infectious disease research?